Navigation Links
IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
Date:6/7/2012

NEW YORK, June 7, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC) announced today that Dr. Arnold I. Caplan has joined its Scientific Advisory Board.  Dr. Steven Victor, CEO of IntelliCell, stated "Dr. Caplan's expertise in regenerative medicine is acknowledged in our entire industry and we are very pleased to have him assist our company as it moves forward.  Dr. Caplan's unique experience in our industry has helped emerging companies take many products from the laboratory and into successful commercialization and our team is looking forward to learning and working with him."  Professor Caplan has lectured and published extensively in the field of regenerative medicine including stem cells, development and bone biology and is recognized as one of the world's foremost authorities on cellular therapies.  Dr. Caplan stated, "The IntelliCell product is a platform for cellular delivery to promote and support the natural regeneration of focal injuries that may occur almost anywhere in the body."  

About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC's) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

About Arnold I. Caplan Ph. D.
Dr. Caplan is a Professor of Biology & General Medical Sciences and Director of the Skeletal Research Center at Case Western Reserve University in Cleveland, Ohio.  Professor Caplan has published over 300 manuscripts and articles in peer reviewed journals.  Dr. Caplan has been Chief Scientific Officer at OrthoCyte Corporation since 2010.  Dr. Caplan co-founded Cell Targeting Inc. and has served as President of Skeletech, Inc. as its founder.  He served as Chief Scientific and founder of Osiris Therapeutics, Inc.  He has served as Director of BioMetic Pharmaceuticals, Inc. and Carbylan Biosurgery.  Also, he has been a Director of Biomimetics Pharmaceuticals, Inc.   Dr. Caplan has served as a Member of the Scientific Advisory Board at IsoTis Orthobiologics.  He is the recipient of several honors and awards from the orthopedic research community.  Dr. Caplan holds a Ph. D. from John Hopkins University Medical School and a B.S. in chemistry from the Illinois Institute of Technology.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contacts:
IntelliCell BioSciences, Inc.
Rubenstein Investor Relations
Contact: Tim Clemensen
Email Contact: TClemensen@rubensteinir.com
(212) 843-9337  

 


'/>"/>
SOURCE IntelliCell BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
2. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
3. Brain Research Foundation Announces Grant To Study Concussive Events Among Grade School Children
4. ERT Announces Clearance from German Federal Cartel Office
5. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
6. American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE
7. SIRO Clinpharm Announces a Fabulous Date With the Dueling Pianos
8. Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension
9. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
10. The Galien Foundation Announces New "Best Medical Technology" Award Category for 2012 Prix Galien USA Awards Program
11. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , Isansys  Lifecare, a new generation ... Engine wireless patient monitoring platform, as it ships more systems ... , Scotland and Norway ... generation system, launched earlier this year, is now being used in ... , This new technology significantly enhances the user experience ...
(Date:5/31/2016)... 2016 194 Mitgliedsstaaten ... Eliminierung von viraler Hepatitis    Am ... eingegangen, virale Hepatitis bis 2030 zu eliminieren. ... Assembly haben sich die Staaten einstimmig dafür entschieden, ... Viral Hepatitis Strategy) zu verabschieden, was das bisher ...
(Date:5/31/2016)... May 31, 2016 RnRMarketResearch.com adds ... with comparative analysis of Asthma therapy at various stages, ... route of administration (RoA) and molecule type, along with ... also reviews key players involved in the therapeutic development ... projects. Complete report on H1 2016 pipeline ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... ... technology solutions to the healthcare industry, The University of Scranton is adding a ... accelerated path to a career in rapidly growing field of healthcare information. ...
(Date:5/30/2016)... ... ... As the CDC relaxes its stance on traditional No-Nit policies, parents wonder ... lice free. , According to a May 26 article from news source ... classroom despite the fact that they may be harboring an infestation. Previous No-Nit policies ...
(Date:5/30/2016)... , ... May 30, 2016 , ... ... 6th, while Shaolin warrior 8-day-8 and 8-night special intensive summer training camp starts ... annual overnight summer camp offers families and children a fun and unique experience ...
(Date:5/29/2016)... North Carolina (PRWEB) , ... May 29, 2016 , ... ... Now, via Amazon.com, their new KlipPro KP-240L clipper is available to the public. This ... which is substantially wider than the average clipper. , Everything about this product ...
(Date:5/28/2016)... ... ... "Color Grading media can be time consuming but with FCPX LUT Night ... Austin - CEO of Pixel Film Studios. , With the FCPX LUT Night ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ...
Breaking Medicine News(10 mins):